Free Trial
→ I have publicly predicted six major American crashes, before each one happened. (From Weiss Ratings) (Ad)tc pixel
NASDAQ:BFRI

Biofrontera Q3 2026 Earnings Date & Estimates

Biofrontera logo
$0.83 -0.06 (-6.52%)
As of 03:20 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Biofrontera is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 10:00 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
10:00 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Biofrontera in Q3 2026

Biofrontera is expected to post earnings of -$0.22 per share on revenue of $8.25 million. In the same quarter a year earlier Biofrontera reported -$0.59 per share on revenue of $6.99 million. Biofrontera last reported on August 13, 2026, posting -$0.05 per share and beating the -$0.1050 consensus estimate. Biofrontera has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.22
Expected Revenue
$8.25 million
Prior-Year EPS
-$0.59
Prior-Year Revenue
$6.99 million
Expected Revenue Growth
+18.1%

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.05 (Beat by +$0.0550)
Last Quarter Revenue
$12.00 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Biofrontera Q3 2026 Earnings FAQ

Biofrontera (NASDAQ:BFRI) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Biofrontera's Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 10:00 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Biofrontera to post earnings of -$0.22 per share for Q3 2026.

The consensus revenue estimate for Biofrontera is $8.25 million for Q3 2026.

Biofrontera Earnings Headlines

Biofrontera Inc. (NASDAQ:BFRI) Stock Short Interest Report for September
October 12 at 12:41 PM  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31111747
Biofrontera Submits Ameluz SNDA For Expanded Actinic Keratosis Use
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697589/biofrontera-submits-ameluz-snda-for-expanded-actinic-keratosis-use.aspx
A new income category is drawing serious money - here's why
Forbes recently called a new category of exchange-traded income funds a 'golden era,' and Bloomberg noted the eye-popping yields are fueling a boom among everyday investors. Three years ago, barely a dozen of these funds existed - today there are more than 100, holding over $140 billion. These funds trade on the NYSE and NASDAQ and are built to generate monthly income. Some investors are targeting $5,000 a month with roughly one-tenth of the nest egg Wall Street says you need.tc pixel
October 14 at 1:00 AM  |  Investors Alley (Ad)
Biofrontera Files SNDA To Expand Ameluz Use In Actinic Keratosis; Stock Down
October 8, 2026  |  rttnews.comhttps://www.rttnews.com/3697609/biofrontera-files-snda-to-expand-ameluz-use-in-actinic-keratosis-stock-down.aspx
Biofrontera Inc. Submits sNDA to Expand Ameluz® PDT for Actinic Keratoses Beyond the Face and Scalp
October 8, 2026  |  quiverquant.comQ
Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
October 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/08/3377367/0/en/biofrontera-submits-supplemental-new-drug-application-to-fda-to-expand-ameluz-red-light-pdt-to-actinic-keratoses-on-the-full-body.html
See More Biofrontera Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Biofrontera? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Biofrontera and other key companies, straight to your email.

About Biofrontera

Biofrontera (NASDAQ:BFRI) (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing dermatology products in the United States. The company’s activities center on treatments for actinic keratosis, a common precancerous skin condition caused by sun exposure.

Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription treatment used in combination with photodynamic therapy to treat mild-to-moderate actinic keratoses on the face and scalp. The company also markets the BF-RhodoLED and RhodoLED XL medical light systems, which are used to activate Ameluz during the photodynamic therapy procedure.

Biofrontera’s operations are primarily focused on the U.S. dermatology market, where it sells its products through commercial and medical-affairs activities directed at dermatologists and other healthcare professionals. The company’s U.S. business has roots in the broader Biofrontera group, which was founded in Germany and developed Ameluz and related photodynamic-therapy technologies.

View Biofrontera Profile
Earnings Tools